From missed red flags to insurance denials, the barriers to ATTR-CM care are multi-level. Drs Alexander and Pino-Moreno break down what’s failing and how to fix it.

Patients with MASLD often underreport alcohol use and even modest intake can block improvement. Drs VanWagner and Ajmera share practical tools to quantify intake, spot MetALD, and counsel patients effectively.

MASLD is a silent condition and labs may look normal. Drs VanWagner and Shubrook walk through who to screen, how to use FIB-4, and when primary care can manage MASLD without a specialist.

Dr Yash Varma, a chief cardiology fellow, asks Dr Ileana Piña for her insights on when a patient with heart failure should be referred for advanced therapies.

Chief Cardiology fellow Yash Varma asks HF expert Ileana Piña for tips on when patients are stable to discharge on guideline-directed medical therapy and if it’s ever ok to de-escalate.

In this DDW 2026 update, Dr David Johnson reviews key advances in cirrhosis care, GLP-1 benefits, earlier HCC detection, colorectal cancer risks, and IL-23-targeted IBD therapies.

Chief fellow Yash Varma asks heart failure expert Ileana Piña for her tips and tricks in managing patients admitted with acute decompensated heart failure.

ATTR-CM is the zebra hiding among the horses. AI may finally be the tool that finds it. Experts Drs Kevin Alexander and Lily Stern explore what's working, what's not, and what comes next.

In the latest Skills Lab, Dr Bishal Gyawali breaks down effect size in oncology, revealing how overpowered trials can turn trivial gains into 'significant' results.

John Mandrola discusses the sham-controlled trial of percutaneous coronary intervention for chronic total occlusions with ORBITA-CTO investigators Sarosh Khan and John Davies.